Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CEO Of Australia’s Angenix Biotech Charged With Fraud

This article was originally published in PharmAsia News

Executive Summary

The CEO of Australian biotech Angenix has been charged in a Queensland court with defrauding his company of nearly $3.4 million. CEO Neil Leggett declined comment, saying he had not yet retained an attorney. The charge carries a maximum penalty of 12 years in jail. One of Angenix's prime products is ThromboView for detecting blood clots such as those that develop during long plane flights. Angenix also had been looking to enter the Chinese market with its drugs. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel